000			nab a22 7a 4500
999			_c17514 _d17514
003			PC17514
005			20230619113206.0
008			230619b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91930 _aRomero Otero, Javier _eUrología
100			_92125 _aGarcía Gómez, Borja _eUrología
100			_91980 _aDuarte Ojeda, José Manuel _eUrología
100			_91692 _aRodríguez Antolín, Alfredo _eUrología
245	0	0	_aActive surveillance for prostate cancer. _h[revisión]
260			_bInternational journal of urology : official journal of the Japanese Urological Association, _c2016
300			_a23(3):211-8.
500			_aFormato Vancouver: Romero Otero J, García Gómez B, Duarte Ojeda JM, Rodríguez Antolín A, Vilaseca A, Carlsson SV et al. Active surveillance for prostate cancer. Int J Urol. 2016 Mar;23(3):211-8.
501			_aPMID: 26621054 PMC4966658
504			_aContiene 71 referencias
520			_aIt is worth distinguishing between the two strategies of expectant management for prostate cancer. Watchful waiting entails administering non-curative androgen deprivation therapy to patients on development of symptomatic progression, whereas active surveillance entails delivering curative treatment on signs of disease progression. The objectives of the two management strategies and the patients enrolled in either are different: (i) to review the role of active surveillance as a management strategy for patients with low-risk prostate cancer; and (ii) review the benefits and pitfalls of active surveillance. We carried out a systematic review of active surveillance for prostate cancer in the literature using the National Center for Biotechnology Information's electronic database, PubMed. We carried out a search in English using the terms: active surveillance, prostate cancer, watchful waiting and conservative management. Selected studies were required to have a comprehensive description of the demographic and disease characteristics of the patients at the time of diagnosis, inclusion criteria for surveillance, and a protocol for the patients' follow up. Review articles were included, but not multiple papers from the same datasets. Active surveillance appears to reduce overtreatment in patients with low-risk prostate cancer without compromising cancer-specific survival at 10 years. Therefore, active surveillance is an option for select patients who want to avoid the side-effects inherent to the different types of immediate treatment. However, inclusion criteria for active surveillance and the most appropriate method of monitoring patients on active surveillance have not yet been standardized.
710			_9220 _aServicio de Urología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966658/pdf/nihms-764091.pdf _yAcceso libre
942			_2ddc _cREV _n0